Literature DB >> 23312984

Ventricular hypertrophy and left atrial dilatation persist and are associated with reduced survival after valve replacement for aortic stenosis.

Jocelyn M Beach1, Tomislav Mihaljevic2, Jeevanantham Rajeswaran3, Thomas Marwick4, Samuel T Edwards1, Edward R Nowicki5, James Thomas4, Lars G Svensson5, Brian Griffin4, A Marc Gillinov5, Eugene H Blackstone6.   

Abstract

OBJECTIVES: We sought to understand the factors modulating left heart reverse remodeling after aortic valve replacement, the relationship between the preoperative symptoms and modulators of left heart remodeling, and their influence on long-term survival.
METHODS: From October 1991 to January 2008, 4264 patients underwent primary aortic valve replacement for aortic stenosis. Changes in the time course of left ventricular reverse remodeling were assessed using 5740 postoperative transthoracic echocardiograms from 3841 patients.
RESULTS: Left ventricular hypertrophy rapidly declined after surgery, from 137 ± 42 g/m(2) preoperatively to 115 ± 27 by 2 years and remained relatively constant but greater than the upper limit of normal. The most important risk factor for residual left ventricular hypertrophy was greater preoperative left ventricular hypertrophy (P < .0001). Other factors included a greater left atrial diameter (reflecting diastolic dysfunction), a lower ejection fraction, and male gender. An increased postoperative transprosthesis gradient was associated with greater residual left ventricular hypertrophy; however, its effect was minimal. Preoperative severe left ventricular hypertrophy and left atrial dilatation reduced long-term survival, independent of symptom status.
CONCLUSIONS: Severe left ventricular hypertrophy with left atrial dilatation can develop from severe aortic stenosis, even without symptoms. These changes can persist, are associated with decreased long-term survival even after successful aortic valve replacement, and could be indications for early aortic valve replacement if supported by findings from an appropriate prospective study.
Copyright © 2014 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  18; AV; AV replacement; AVR; LA; LV; LV ejection fraction; LV mass index; LVEF; LVMI; TTE; aortic valve; left atrial; left ventricular; transthoracic echocardiogram

Mesh:

Year:  2013        PMID: 23312984     DOI: 10.1016/j.jtcvs.2012.12.016

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  33 in total

1.  Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement.

Authors:  Taku Inohara; Pratik Manandhar; Andrzej S Kosinski; Roland A Matsouaka; Shun Kohsaka; Robert J Mentz; Vinod H Thourani; John D Carroll; Ajay J Kirtane; Joseph E Bavaria; David J Cohen; Todd L Kiefer; Jeffrey G Gaca; Samir R Kapadia; Eric D Peterson; Sreekanth Vemulapalli
Journal:  JAMA       Date:  2018-12-04       Impact factor: 56.272

2.  Long-term durability of bioprosthetic aortic valves: implications from 12,569 implants.

Authors:  Douglas R Johnston; Edward G Soltesz; Nakul Vakil; Jeevanantham Rajeswaran; Eric E Roselli; Joseph F Sabik; Nicholas G Smedira; Lars G Svensson; Bruce W Lytle; Eugene H Blackstone
Journal:  Ann Thorac Surg       Date:  2015-02-04       Impact factor: 4.330

3.  Commentary: Alas, we are not yet zebrafish.

Authors:  Christopher T Ryan; Todd K Rosengart
Journal:  J Thorac Cardiovasc Surg       Date:  2020-01-07       Impact factor: 5.209

Review 4.  Cardiac inositol 1,4,5-trisphosphate receptors.

Authors:  M Iveth Garcia; Darren Boehning
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2016-11-22       Impact factor: 4.739

5.  Predictions of hypertrophy and its regression in response to pressure overload.

Authors:  Kyoko Yoshida; Andrew D McCulloch; Jeffrey H Omens; Jeffrey W Holmes
Journal:  Biomech Model Mechanobiol       Date:  2019-12-07

Review 6.  Challenges and opportunities in improving left ventricular remodelling and clinical outcome following surgical and trans-catheter aortic valve replacement.

Authors:  Xu Yu Jin; Mario Petrou; Jiang Ting Hu; Ed D Nicol; John R Pepper
Journal:  Front Med       Date:  2021-05-28       Impact factor: 4.592

7.  Coronary artery disease and outcomes of aortic valve replacement for severe aortic stenosis.

Authors:  Jocelyn M Beach; Tomislav Mihaljevic; Lars G Svensson; Jeevanantham Rajeswaran; Thomas Marwick; Brian Griffin; Douglas R Johnston; Joseph F Sabik; Eugene H Blackstone
Journal:  J Am Coll Cardiol       Date:  2013-02-26       Impact factor: 24.094

8.  Probability of atrial fibrillation after ablation: Using a parametric nonlinear temporal decomposition mixed effects model.

Authors:  Jeevanantham Rajeswaran; Eugene H Blackstone; John Ehrlinger; Liang Li; Hemant Ishwaran; Michael K Parides
Journal:  Stat Methods Med Res       Date:  2016-01-05       Impact factor: 3.021

Review 9.  Calcific Aortic Valve Disease: Part 2-Morphomechanical Abnormalities, Gene Reexpression, and Gender Effects on Ventricular Hypertrophy and Its Reversibility.

Authors:  Ares Pasipoularides
Journal:  J Cardiovasc Transl Res       Date:  2016-05-16       Impact factor: 4.132

10.  Long-term survival, valve durability, and reoperation for 4 aortic root procedures combined with ascending aorta replacement.

Authors:  Lars G Svensson; Saila T Pillai; Jeevanantham Rajeswaran; Milind Y Desai; Brian Griffin; Richard Grimm; Donald F Hammer; Maran Thamilarasan; Eric E Roselli; Gösta B Pettersson; A Marc Gillinov; Jose L Navia; Nicholas G Smedira; Joseph F Sabik; Bruce W Lytle; Eugene H Blackstone
Journal:  J Thorac Cardiovasc Surg       Date:  2015-11-10       Impact factor: 5.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.